Bank of New York Mellon
VERV

Bank of New York Mellon’s Verve Therapeutics VERV Stock Holding History

Bank of New York Mellon’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-220,788
Closed -$2.48M – 4266
2025
Q2 		$2.48M Sell
220,788
-4,246
-2% -$24.2K ﹤0.01% 2640
2025
Q1 		$1.03M Buy
225,034
+4,532
+2% +$30.4K ﹤0.01% 3052
2024
Q4 		$1.24M Buy
220,502
+5,262
+2% +$29.7K ﹤0.01% 3022
2024
Q3 		$1.04M Sell
215,240
-59,633
-22% -$346K ﹤0.01% 3123
2024
Q2 		$1.34M Buy
274,873
+49,922
+22% +$314K ﹤0.01% 3022
2024
Q1 		$2.99M Buy
224,951
+24,776
+12% +$329K ﹤0.01% 2557
2023
Q4 		$2.79M Buy
200,175
+12,983
+7% +$161K ﹤0.01% 2658
2023
Q3 		$2.48M Buy
187,192
+407
+0.2% +$6.55K ﹤0.01% 2688
2023
Q2 		$3.5M Buy
186,785
+15,636
+9% +$260K ﹤0.01% 2517
2023
Q1 		$2.47M Sell
171,149
-3,243
-2% -$63.5K ﹤0.01% 2681
2022
Q4 		$3.37M Buy
174,392
+4,514
+3% +$120K ﹤0.01% 2558
2022
Q3 		$5.83M Buy
169,878
+66,322
+64% +$2.12M ﹤0.01% 2214
2022
Q2 		$1.58M Sell
103,556
-12,231
-11% -$189K ﹤0.01% 2963
2022
Q1 		$2.64M Buy
115,787
+36,652
+46% +$1.05M ﹤0.01% 2785
2021
Q4 		$2.92M Buy
79,135
+22,877
+41% +$961K ﹤0.01% 2762
2021
Q3 		$2.64M Buy
+56,258
New +$3.31M ﹤0.01% 2833

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of New York Mellon's VERV Position: Q3 2025 in Review

Bank of New York Mellon sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 220,788 shares — an estimated $2.48M sold.

Bank of New York Mellon first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $5.83M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Bank of New York Mellon reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 220,788 Verve Therapeutics shares in Q3 2025, an estimated $2.48M.
  • Bank of New York Mellon first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Bank of New York Mellon's Verve Therapeutics position peaked at $5.83M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.